金輝控股(09993.HK)設立資產支持專項計劃
格隆匯9月16日丨金輝控股(09993.HK)公吿,董事會欣然宣佈,"中金-金輝-北京金輝大廈資產支持專項計劃"已於2021年9月16日設立。中國國際金融股份有限公司擔任資產支持專項計劃的管理人。涉及中國證券投資基金業協會的相關存檔備案程序預期將於資產支持專項計劃設立後25個工作日內完成。
根據資產支持專項計劃,公司間接非全資附屬公司金輝集團股份有限公司將向合資格投資者發行北京金輝大廈資產支持證券("資產支持證券")。資產支持專項計劃的發行總規模為人民幣38億元,資產支持證券預計於2021年10月25日在上海證券交易所上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.